A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 in Patients With Chronic Hepatitis B.
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2018
At a glance
- Drugs APG 1387 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Ascentage Pharma
- 11 Jul 2018 Status changed from planning to recruiting.
- 26 Feb 2018 New trial record
- 13 Feb 2018 According to the Ascentage Pharma media release, China Food and Drug Administration (CFDA) has accepted the Investigational New Drug (IND) application for APG-1387 for the treatment of the Hepatitis B virus (HBV) infection.